Differential regulation of indoleamine 2,3-dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells  by Jung, In Duk et al.
FEBS Letters 581 (2007) 1449–1456Diﬀerential regulation of indoleamine 2,3-dioxygenase
by lipopolysaccharide and interferon gamma in murine bone
marrow derived dendritic cells
In Duk Junga, Chang-Min Leea, Young-Il Jeongb, Jun Sik Leec, Won Sun Parkd,
Jin Hand, Yeong-Min Parka,*
a Department of Microbiology and Immunology and National Research Laboratory of Dendritic, Cell Diﬀerentiation and Regulation,
Medical Research Institute, Pusan National University, College of Medicine, Ami-dong 1-10, Seo-gu, Busan 602-739, South Korea
b Department of Microbiology, Pusan National University, College of Natural Science, Geumjeong-gu, Busan 609-735, South Korea
c Department of Pharmacy, Pusan National University, College of Pharmacy, Geumjeong-gu, Busan 602-735, South Korea
d Mitochondria Signaling Laboratory, FIRST Project Group, Department of Physiology and Biophysics, Inje University, College of Medicine,
Gaegeum-dong, Busnajin-Gu, Busan 614-735, South Korea
Received 11 December 2006; revised 26 February 2007; accepted 27 February 2007
Available online 7 March 2007
Edited by Beat ImhofAbstract Indoleamine 2,3-dioxygenase (IDO) is a rate-limiting
enzyme in the L-tryptophan-kynurenine pathway, which converts
an essential amino acid, L-tryptophan, to N-formylkynurenine.
The expression of IDO increases when inﬂammation is induced
by wounding, infection or tumor growth. Although recent studies
have suggested that IDO expression is up-regulated by IFN-c in
various cell types and that the induction of IDO can also be med-
iated through an IFN-c-independent mechanism, these mecha-
nisms still remain unknown. In this study, we investigated
whether lipopolysaccharide (LPS) induces the expression of
IDO through an IFN-c-mediated signaling pathway or not.
IFN-c-induced expression of IDO expression was inhibited only
by JAK inhibitor I. However, LPS-induced expression of IDO
was inhibited by LY294002 and SP600125 but not by JAK inhib-
itor I, SB203580, or U0126. These ﬁndings clearly indicate that
LPS can induce the IDO expression via an IFN-c-independent
mechanism and PI3 kinase and JNK in the LPS-induced path-
way leading to IDO expression.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Indoleamine 2,3-dioxygenase (IDO) is an enzyme that medi-
ates the initial and rate-limiting step in the catabolism of tryp-
tophan along the kynurenine pathway [1]. It is well-known that
pro-inﬂammatory mediators such as endotoxin and interferon-
c (IFN-c) induce the expression of IDO in several tissues. The
biological role of IDO in the immune system has been impli-
cated in the inhibition of T cell proliferation by trytophan
catabolism, which protects the fetus from maternal responses.
Previous studies have shown that human dendritic cells (DCs)
expressing signiﬁcant IDO activity can mediate the inhibition
of T cell proliferation through the degradation of tryptophan
[2]. The overall immunosuppressive eﬀects of IDO are not en-*Corresponding author. Fax: +82 51 243 2259.
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expressing cell [3]. Although the mechanism of IDO induction
in vivo is not completely clear, it is widely accepted that inter-
ferons, particularly IFN-c, are essential stimulators for IDO
induction [4].
IFN-c signals through a pair of receptor subunits compris-
ing IFN-cR1 and IFN-cR2. The IFN-cR1 subunit is constitu-
tively associated with Jak1, whereas IFN-cR2 is associated
with Jak2 [5]. The binding of IFN-c to IFN-c R results in
the cross-activation of these Jak protein tyrosine kinases,
which then phosphorylate downstream substrates such as
Stat1 and Stat2 [5]. According to the above signaling pathway,
IFN-c induces the expression of a number of cellular genes,
resulting in induced synthesis of many gene products, includ-
ing MHC classes [6–8], Fc receptors [9], enzyme activity, e.g.
IDO [10] and many other proteins of unknown function [11].
It has previously been reported that IDO induction can also
be mediated through an IFN-c-independent mechanism under
certain circumstances [12,13]. However, little is known about
the signal transduction mechanism responsible for LPS-in-
duced expression of IDO, which occurs through an IFN-c-
independent mechanism. Fujigaki et al. [14] reported that
LPS-induced IDO expression is not regulated by an IFN-c-
dependent mechanism, and may be related to the activities of
the p38 MAPK pathway and NF-jB.
A variety of signaling pathways in the response to LPS have
been well-elucidated; this pathway leads to the activation of
NF-jB via Toll-like receptor 4 (TLR4). Although the NF-jB
pathway is undoubtedly the key factor in the response to LPS,
the role of the MAPK pathways is less certain. Mitogen-acti-
vated protein kinases (MAPKs) are involved in perpetuating
the inﬂammatory response, and are activated through well-de-
ﬁned signaling pathways [15]. When MyD88 knockout mice
were stimulated with LPS, LPS-induced activation of MAPK
was delayed compared with wild-type mice, which suggested
that MyD88 is involved, but is not a necessary molecule [16].
Moreover, Mal/Tirap, an adaptor molecule that is homologous
to MyD88, has been shown to be involved in the activation of
MAPKs by TLR4 [17]. PI3K is a mediator for TLR4-MyD88-
mediated JNK activation after LPS stimulation inmacrophages
[18], although upstream molecules in the JNK pathway in boneblished by Elsevier B.V. All rights reserved.
1450 I.D. Jung et al. / FEBS Letters 581 (2007) 1449–1456marrow derived dendritic cells (BMDCs) are unknown. We
queried whether JNK may also be involved in LPS-induced
expression of IDO, and if so, whether PI3K participates in
LPS-induced activation of JNK.
In the present study we show that LPS stimulation induces
IDO gene expression in BMDCs and that this induction occurs
through PI3K- and JNK-dependent pathways. Finally, we
propose that up-regulation of IDO gene expression following
LPS stimulation in BMDCs is mediated by an IFN-c-indepen-
dent mechanism. These studies provide new insights into the
mechanism by which induction of IDO gene expression re-
sponds to LPS in BMDCs.2. Materials and methods
Mice.Male 8-12 weeks-old C57BL/6 (H-2Kb and I-Ab) and BALB/c
(H-3Kd and I-Ad) mice were purchased from the Korean Institute of
Chemistry Technology (Daejeon, Korea). They were housed in a spe-
ciﬁc pathogen-free environment within our animal facility for at least
one week before use.
2.1. Reagents and Abs
Materials were obtained from the following sources: recombinant
mouse (rm) GM-CSF and rmIL-4 were purchased from R&D Systems.
Various inhibitors such as InSolutionTM JAK Inhibitor I, LY294002,
SP600125, SB203580 and U0126 were obtained from Calbiochem (San
Diego, CA); LPS (from Escherichia coli 055:B5) was obtained from
Sigma (St. Louis, MO); FITC- or PE-conjugated anti-CD11c (HL3)
by ﬂow cytometry, as well as isotype-matched control mAbs, biotinly-
ated-anti-CD11c (N418) mAbs, were purchased from eBioscience (San
Diego, CA); PE-conjugated anti-p-JNK and anti-p-c-Jun were pur-
chased from Santa Cruz (Santa Cruz, CA); Mouse anti-IDO monoclo-
nal Ab and FITC-conjugated Goat anti-Mouse IgG were purchased
form Chemicon International (Temecula, CA). anti-phospho-ERK,
anti-ERK, anti-phospho-p38, anti-p38, anti-phospho-JNK, anti-
JNK, anti-phospho-Akt, anti-Akt and a-tubulin were purchased from
Santa Cruz.
2.2. Generation and culture of DCs
DCs were generated from murine BM cells according to the proce-
dure of Inaba et al. [19] with minor modiﬁcation. Brieﬂy, BM was
ﬂushed from the tibiae and femurs of 6-8 weeks male C57BL/6 and
depleted of red blood cells with Red Blood cell Lysing buﬀer (Sigma).
The cells were plated in 6-well culture plates (1 · 106cells/ml; 2 ml/well)
in RPMI supplemented with 10% heat-inactivated FBS, 100 U/ml pen-
icilline, 100 mg/ml stereptomycin, 20 ng/ml rmGM-CSF and 10 ng/ml
rmIL-4 at 37 C in 5% CO2. On days 3 and 5 of the culture, ﬂoating
cells were gently removed and fresh medium was added. On day 6 of
the culture, non-adherent cells and loosely adherent proliferating DC
aggregates were harvested for analysis or stimulation. On day 7, 80%
or more of the non-adherent cells expressed CD11c.
2.3. PI3 Kinase activity
PI3K activity was evaluated by competitive ELISA (Echelon Biosci-
ences). Cells were washed 3· in iced buﬀer (in mmol/L: 137 NaCl, 20
Tris–HCl, pH 7.4, 1 CaCl2, 1 MgCl, and 0.1 Na3VO4), lysed by addi-
tion of 1% NP-40 and 1 mmol/L PMSF, and lysates centrifuged for
10 min at 13000 rpm at 4 C. PI3K pulled down by anti-PI3K p85
antibody (Upstate Biotechnology) and protein A/G beads (Santa Cruz
Biotechnology) from 100-lg cell lysates. PI3K activity was assessed
using phosphatidylinositol 4,5 bisphosphate as the substrate.
2.4. Quantitative real-time PCR
IDO PCR primers used were as follows: forward 5 0-GTACATC-
ACCATGGCGTATG-3 0, reverse 5 0-CGAGGAAGAAGCCCTTG-
TC-3 0. Quantitative amounts of each gene was standardized against
the GAPDH housekeeping gene. Real-time PCR was performed using
a BioRad MiniOpticon System (BioRad Laboratories Ltd.) with
SYBR green ﬂuorophore. Reactions were performed in a total volumeof 20 ll-including 10 ll 2· SYBR Green PCR Master Mix (Applied
Biosystems), 1 ll of each primer at 10 lM concentration and 1 ll of
the previously reverse-transcribed cDNA template. The protocols used
are as follows: denaturation (95 C for 10 min), ampliﬁcation repeated
40 times (95 C for 30 s, 52 C for 30 s, 72 C for 30 s, and acquisition
temperature for 15 s). For each sample, ddCt (crossing point) values
were calculated as the Ct of the target gene minus the Ct of the
GAPDH gene. Gene expression was derived according to the equation
2ddCt; changes in gene expression were expressed as relative to basal.
2.5. Flow cytometry
Cells (1 · 105) were washed in PBS containing 0.1% sodium azide
and incubated with 10% (v/v) normal goat serum to block non-speciﬁc
binding of IgG for 15 min at 4 C and stained with FITC- or PE-con-
jugated mAbs CD11c (N418) for 30 min at 4 C. For Intracellular
staining of IDO, p-JNK and p-c-Jun were assayed by ﬂow cytometry
as previously reported [20]. The cells (1 · 105) were analyzed using
the FACS Calibur (Becton-Dickinson).
2.6. In vivo treatment of JNK inhibitor, SP600125 in mice
JNK inhibitor (SP600125, 30 mg/kg intraperitoneal injection),
unlike older non-speciﬁc inhibitors, has been shown to be speciﬁc for
JNK activity at the concentrations used herein [21,22]. The dose was
chosen on the basis of previous in vivo studies that showed 30 mg/kg
inhibited JNK activity [22]. For analysis of intracellular IDO expres-
sion in splenic DCs using ﬂow cytometry, Mice were intraperitoneally
injected with SP600125 (30 mg/kg) for 12 h before the administration
of 1 mg/kg of LPS. After 18 h from LPS challenge, spleens from mice
were taken out. Their spleens were disrupted and the cells were centri-
fuged at 400·g for 5 min and remove red blood cells from mouse
splenocytes by treatment of red blood cell lysing buﬀer (Sigma–
Aldrich, St. Louis, MO, USA). And then the cells were harvested
and washed twice with phosphate buﬀered saline (PBS) containing
with 2% fetal bovine serum and 0.1% sodium azide.
2.7. Statistical analysis
Experiments were repeated at least three times with consistent re-
sults. Unless otherwise stated, data are expressed as the means ±
S.E.M. ANOVA was used to compare experimental groups to control
values. While comparisons between multiple groups were done using
Tukey’s Multiple Comparison test. Statistical signiﬁcance was deter-
mined as P value less than 0.05.3. Results
3.1. LPS and IFN-c induces IDO Expression on BMDCs in a
dose-dependent fashion
Initially, we performed dose-response studies of LPS- and
IFN-c-induced IDO expression on BMDCs using quantitative
real-time PCR and ﬂow cytometry. BMDCs were cultured with
LPS (0–800 ng/ml) or IFN-c (0–400 U/ml) for 24 h. Fig. 1A
shows that the level of IDO mRNA expression by LPS or
IFN-c was enhanced in a dose-dependent manner. In particu-
lar, the level of IDO mRNA in BMDCs treated with LPS or
IFN-c stimulation was maximal at 200 ng/ml (4.86-fold induc-
tion) or 100 U/ml (12.65-fold induction), respectively. Fig. 1B
shows that the level of IDO protein production induced by
LPS or IFN-c was enhanced in a dose-dependent manner.
The induction of IDO protein by LPS and IFN-c was maximal
at 200 ng/ml (Fig. 1B-d) and 100 U/ml (Fig. 1B-i), respectively.
Therefore, we decided to use a suboptimal dose of LPS, as
200 ng/ml, and of IFN-c, as 100 U/ml, for the later experiments.3.2. LPS increases IDO expression via an IFN-c-independent
mechanism in BMDCs
Since PI3K is one of the major target molecules in TLR4-
mediated signaling in various cell types [23,24] and JAK is
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Fig. 1. Eﬀects of LPS and IFN-c on IDO expression in murine BMDCs. (A) DCs were treated with indicated concentrations of LPS or IFN-c for
24 h, and then cells were harvested and total RNA was extracted. Quantitative mRNA expression was measured as described in Section 2. (B) DCs
were treated with indicated concentrations of LPS and IFN-c for 24 h, and then cells were harvested and analyzed by ﬂow cytometry. The cells were
gated on CD11c+. Values are means ± S.E.M. obtained from at least three separate experiments. The asterisks in panel A indicate signiﬁcant
increases compared to that of non-treated DCs at P < 0.05 (*) and 0.001 (***).
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sought to determine whether IDO expression by LPS stimula-
tion is mediated by TLR4 or IFN-cR1 in BMDCs. Accord-
ingly, we used LY294002 as a PI3K inhibitor and JAK
inhibitor I as a JAK inhibitor. Fig. 2A shows that LPS-in-
duced IDO mRNA expression was completely inhibited by
only LY294002, but not by JAK inhibitor I at the concentra-
tion at which IFN-c-induced IDO gene expression was abol-
ished. In contrast, IFN-c-induced IDO mRNA expression
was inhibited by only JAK inhibitor I but not by LY294002.
As shown in Fig. 2B, the protein level of IDO induced by
LPS stimulation was also completely inhibited in LPS-treated
DCs in the presence of LY294002 (Fig. 2B-e) but not in the
presence of JAK inhibitor I (Fig. 2B-h). However, the protein
level of IDO induced by IFN-c stimulation was completely
inhibited in IFN-c-treated DCs in the presence of the JAK
inhibitor I (Fig. 2B-i) but not in the presence of LY294002
(Fig. 2B-f). Next, to test whether PI3 kinase is activated by
exposure to LPS in murine dendritic cells, we examined the
time course of PI3 kinase activity after LPS stimulation.
LPS-induced PI3 kinase activation reached a maximum value
at 15 min after LPS stimulation, and decreased thereafter
(Fig. 2C). One of the downstream targets of PI3 kinase is
Akt/protein kinase B [25]. To conﬁrm the eﬀect of LPS on
PI3 kinase activity, PI3 kinase activation was evaluated byWestern blot analysis of the phosphorylated Akt after LPS
exposure in DCs. As shown in Fig. 2D, the phosphorylation
of Akt tended to increase with 5 min of exposure to LPS and
increased at 30 min of LPS incubation. The phosphorylation
of Akt remained close to this level thereafter. In addition,
DCs were treated 1 h before LPS stimulation with PI3K inhib-
itor, LY294002 (10 lM). Incubation with LY294002 resulted
in marked inhibition of Akt phosphorylation (Fig. 2E). These
data suggest that LPS-induced expression of IDO is regulated
by PI3K, and may not be regulated by IFN-c-mediated JAK
signaling.3.3. JNK is involved in LPS-induced IDO gene expression in
BMDCs
To examine the possible role of MAPK in the signal trans-
duction responsible for LPS- or IFN-c-induced IDO expres-
sion, we analyzed the eﬀect of three diﬀerent MAPK
inhibitors; SP600125 as a JNK inhibitor, SB203580 as a p38
MAPK inhibitor, and U0126 as an ERK1/2 inhibitor. The re-
sults show that these inhibitors have no inhibitory eﬀect on
IFN-c-induced IDO expression, suggesting that MAPKs are
not involved in the induction of IDO expression by IFN-c
(Fig. 3A, right and B-f,i,l). However, LPS-induced IDO
expression was down-regulated by only SP600125, which
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Fig. 2. Eﬀects of PI3K and JAK on LPS- and IFN-c-induced IDO expression in murine BMDCs. (A) DCs were pre-incubated with LY294002
(10 lM) and JAK inhibitor I (1 lM) for 1 h and further incubated with or without LPS (200 ng/ml) and IFN-c (100 U/ml) for 24 h, and then cells
were harvested and total RNA was extracted. Quantitative mRNA expression was measured as described in Section 2. (B) DCs were pre-incubated
with LY294002 (10 lM) and JAK inhibitor I (1 lM) for 1 h and further incubated with or without LPS (200 ng/ml) and IFN-c (100 U/ml) for 24 h,
and then cells were harvested and analyzed by ﬂow cytometry. The cells were gated on CD11c+. (C) DCs were treated with 200 ng/ml LPS for the
indicated amounts of time. Enzyme immunoassay of PIP3 generation by PI3 kinase in DCs extracts as described in Section 2. (D) DCs were treated
with 200 ng/ml LPS for the indicated amounts of time. The levels of phosphorylated Akt and total Akt were measured by Western blot analysis with
rabbit anti-p-Akt1/2/3 (Thr 308) antibody and mouse anti-Akt1. (E) DCs were pre-incubated with LY294002 (LY, 10 lM) for 1 h and further
incubated with or without LPS (200 ng/ml) for 30 min, and then cells were harvested. The levels of phosphorylated Akt and total Akt were measured
by Western blot analysis with rabbit anti-p-Akt1/2/3 (Thr 308) antibody and mouse anti-Akt1. Values are means ± S.E.M. obtained from at least
three separate experiments. The asterisks in panel A indicate signiﬁcant increases compared to that of LPS- or IFN-c-treated DCs at P < 0.001 (***)
and P > 0.05 (n.s) and for panel C, asterisks indicate signiﬁcant increases compared to 0 min at P < 0.001 (***), P < 0.05 (**) and P > 0.05 (n.s).
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sion by LPS stimulation (Fig. 3A, left and B-e). To further
investigate the inhibitory eﬀect of a JNK inhibitor,
SP600125, on the expression of IDO induced by LPS, we next
assessed the IDO expression in spleenocyte DCs of mice chal-
lenged with LPS in vivo. Inbred C57BL/6J mice were injected
intraperitoneally with SP600125 (30 mg/kg) for 6 h prior to
exposure to LPS, and IDO expression in their spleens was ana-
lyzed 18 h later by ﬂow cytometry. We measured the percent-
age of IDO+/CD11c+ DCs in the spleen by ﬂow cytometry.
As might have been expected, the expression of IDO increased
in mice treated with LPS. Similar to the inhibitory eﬀect of
SP600125 on the expression of IDO in BMDCs in vitro,SP600125 inhibited IDO expression in CD11c+ DCs of the
spleen compared to that of LPS-challenged mice (Fig. 3C).
Next, to test the speciﬁcity of MAPK inhibitors such as JNK
inhibitor (SP600125), p38 MAPK inhibitor (SB203580) and
ERK1/2 inhibitor (U0126), we measured the phosphorylation
of JNK, p38 MAPK and ERK1/2 by LPS stimulation in the
presence and absence of each inhibitor (Fig. 3D). The phos-
phorylation of all MAPKs was activated by stimulation with
LPS for 30 min. SP600125 inhibited only the phosphorylation
of JNK, SB203580 inhibited only the phosphorylation of p38
MAPK and U0126 inhibited the phosphorylation of ERK1/2
indicating that each inhibitor very eﬀectively impaired the
activity of each MAPK in our system. These data suggested
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DCs.
3.4. The relationship between PI3K and JNK/c-Jun in DCs
To determine the relationship between PI3K and JNK/c-Jun
in this signaling pathway, we measured the level of JNK and c-
Jun phosphorylation by ﬂow cytometry. Fig. 4A shows the
time course of activation of the JNK and c-Jun in BMDCs
treated with LPS for indicated amounts of time. The phos-
phorylation of JNK and c-Jun by LPS was stimulated within
5 min (Fig. 4A-b,g) and slightly increased in stimulation after
approximately 30 min. We also measured the phosphorylation
of JNK induced by LPS stimulation, as analyzed by Western
blot to avoid non-speciﬁc binding (Fig. 4B). LPS stimulated
the phosphorylation of JNK in a time-dependent manner sim-
ilar to that shown in Fig. 4A. Next, to investigate whether
PI3K is involved in LPS-induced activation of JNK and c-
Jun, we measured the level of JNK and c-Jun phosphorylation
after LPS stimulation for 30 min in the presence and absencep-
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Two unrelated products, wortmannin and LY294002, are
extensively used as pharmacological agents for characterizing
the role of PI3K in cellular signaling [26]. Wortmannin is a
potent, cell-permeable, potent, selective inhibitor of PI3K
(IC50 = 50 nmol/L) and pleckstrin phosphorylation [27]. The
quercetin derivative LY294002 (2-(4-morphlinyl)-8-phenyl-
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BMDCs.60 min
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e
j
p-JNK1
JNK1
0 5 15 30 60 (min)
LPS (200 ng/ml)
p-JNK1
JNK1
Con LPS WT LY WT/LPSLY/LPS
Y294002/LPS
LY294002/LPS
B
D
way. DCs were treated with LPS (200 ng/ml) for indicated time points.
ated on CD11c+. (B) The levels of phosphorylated JNK and total JNK
and rabbit anti-JNK1 antibody. (C) DCs were pre-incubated with
ng/ml) for 30 min, and then cells were harvested and analyzed by ﬂow
th wortmannin (WT, 500 nM) and LY294002 (LY, 10 lM) for 1 h and
were harvested. The levels of phosphorylated JNK and total JNK were
bit anti-JNK1 antibody. Values are means ± S.E.M. obtained from at
I.D. Jung et al. / FEBS Letters 581 (2007) 1449–1456 14554. Discussion
In this study, we have identiﬁed a novel signaling pathway
in LPS-stimulated murine BMDCs inducing the gene expres-
sion of IDO. Our data showed that the activation of PI3K
and JNK/c-Jun is necessary for LPS-induced IDO gene expres-
sion.
Regulation of IDO expression can be mediated by several
cytokines and immunomodulating agents including TNF-a,
IL-1 and LPS. Each of these agents can enhance the amount
of IDO activity induced in IFN-c-treated macrophages in the
THP-1 cell line [29,30]. Babcock and Carlin [31] reported that
IFN-c with IL-1 or TNF-a enhances the activity of IDO
through the transcriptional activity of the IDO promoter re-
gion. Previous reports demonstrated that both IL-2 and IL-
12 increased the IDO via an IFN-c dependent mechanism
[32,33]. On the other hand, the induction of IDO was pre-
vented by IL-4 and TNF-a in human cell lines [34,35]. Very re-
cent studies have suggested that the induction of IDO by LPS
is regulated by an IFN-c-independent mechanism and may be
related to the activity of the p38 MAPK pathway and NF-jB
[36].
Although the diﬀerences in the signaling pathways between
LPS and IFN-c on IDO gene expression remain largely un-
known, our ﬁndings indicated that LPS-induced IDO expres-
sion is mediated by PI3K and JNK whereas IFN-c-induced
IDO expression is regulated by JAK. These results suggest that
LPS and IFN-c belong to diﬀerent signaling pathway responses
of IDO induction in BMDCs. Furthermore, we intended to
demonstrate the possible basis of LPS or IFN-c-induced IDO
gene expression through the alteration of the cellular expression
levels of JNK, p38 MAPK, and ERK1/2. Our study demon-
strates that only the JNK inhibitor, SP600125, signiﬁcantly
inhibits IDO gene expression in LPS-stimulated BMDCs
(Fig. 3A and B). The biological roles of JNKs have been extre-
mely diﬃcult to demonstrate due to a lack of speciﬁc pharma-
cologic inhibitors.
To further conﬁrm the results of our in vitro study (Fig. 3A
and B), we employed one strategy to determine whether LPS-
induced IDO expression was dependent on JNK activation.
We used the available speciﬁc anthrapyrazolone JNK inhibitor
SP600125, a reversible ATP-competitive inhibitor with greater
than 20-fold selectivity compared to other kinases in inhibiting
the action of phospho-JNK but not the expression of phospho-
JNK [21]. Using SP600125, we found that administration of
SP600125 in mice in vivo decreased the expression of IDO
by LPS in spleenocyte dendritic cells (Fig. 3C). However, none
of the MAPKs inhibitors aﬀected IFN-c-induced IDO expres-
sion (Fig. 3B).
Since PI3K has been shown to be crucial for in JNK phos-
phorylation in other cell types after Fc receptor cross-linking
[37] or upon exposure to platelet-derived growth factor [38],
angiotensin II [39], and LPS [23], we found that the PI3K
inhibitors, wortmannin and LY294002, signiﬁcantly inhibited
the phosphorylation of JNK and c-Jun by LPS stimulation
(Fig. 4C and D). Taken together, these results suggest that
only JNK among the MAPKs is strongly involved in LPS-in-
duced IDO gene expression, and indicated that JNK/c-Jun
pathways induced by LPS are modulated by PI3K. Although
LPS-induced IDO expression was completely inhibited by both
LY294002 and SP600125, LY294002 partially inhibited LPS-
induced JNK activation indicating that LPS-induced IDOgene expression via the activation of JNK could be mediated
by a PI3K-dependent or -independent pathway. It has been
demonstrated that RNA-dependent protein kinase (PKR)
mediates the phosphorylation of JNK by speciﬁc proinﬂam-
matory stress stimuli such as LPS, IL-1b, and TNF-a [40].
The innate immune response is initiated by the recognition
of invariant molecular components of infectious agents such
as LPS and double-strand RNA (dsRNA), a common interme-
diate of viral replication [41]. While the receptors for LPS are
extracellular (CD14) and transmembrane proteins (TLR4)
[42], dsRNA only binds to intracellular targets, including
PKR. Upon binding to dsRNA, PKR is activated by auto-
phosphorylation, and subsequently phosphorylates the a-sub-
unit of eukaryotic initiation factor 2 (eIF-2a), thereby
inhibiting translation [43]. Further studies are required to bet-
ter understand the detailed molecular mechanism of IDO gene
expression including the PKR-dependent pathway induced by
LPS in BMDCs.
In summary, we have determined the mechanism by which
LPS induces the expression of IDO in murine BMDCs. We
show that the inhibition of the PI3K and JNK signaling path-
ways is implicated in LPS-induced IDO gene expression, and
that LPS-induced IDO expression is mediated by an IFN-c-
independent mechanism in murine BMDCs.
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